Patricia Guyot
YOU?
Author Swipe
View article: An Indirect Treatment Comparison of Avalglucosidase Alfa versus Cipaglucosidase Alfa Plus Miglustat in Patients with Late-Onset Pompe Disease
An Indirect Treatment Comparison of Avalglucosidase Alfa versus Cipaglucosidase Alfa Plus Miglustat in Patients with Late-Onset Pompe Disease Open
ITCs suggest more favourable respiratory and mobility outcomes with AVA versus Cipa+mig in patients with LOPD, regardless of prior ERT-experience.
View article: Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison
Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison Open
Placebo-adjusted Bucher ITC analyses showed that the likelihood of achieving efficacy outcomes at 16 weeks and maintaining efficacy outcomes at 52 weeks was higher for dupilumab versus lebrikizumab recipients.
View article: Dupilumab Versus Mepolizumab for Chronic Rhinosinusitis With Nasal Polyposis: An Indirect Treatment Comparison
Dupilumab Versus Mepolizumab for Chronic Rhinosinusitis With Nasal Polyposis: An Indirect Treatment Comparison Open
Dupilumab was associated with greater improvements in CRSwNP-related outcomes versus mepolizumab.
View article: PB0195 Efanesoctocog Alfa Versus Emicizumab in the Prophylactic Treatment of Adolescents and Adults with Severe Hemophilia A without Inhibitors: A Matching-Adjusted Indirect Comparison
PB0195 Efanesoctocog Alfa Versus Emicizumab in the Prophylactic Treatment of Adolescents and Adults with Severe Hemophilia A without Inhibitors: A Matching-Adjusted Indirect Comparison Open
Background: Desmopressin (DDAVP) is commonly used for the treatment and prevention of bleeding in type 1 von Willebrand disease (VWD).The standard intravenous dose of DDAVP, established more than 40 years ago, is 0.3 mcg/kg of actual body …
View article: Comparative efficacy and safety of <scp>Gla‐300</scp> versus <scp>IDegAsp</scp> in <scp>insulin‐naïve</scp> people with type 2 diabetes mellitus uncontrolled on oral anti‐diabetics
Comparative efficacy and safety of <span>Gla‐300</span> versus <span>IDegAsp</span> in <span>insulin‐naïve</span> people with type 2 diabetes mellitus uncontrolled on oral anti‐diabetics Open
Aim To compare the efficacy and safety of insulin glargine‐300 once daily (Gla‐300) with insulin degludec/aspart (IDegAsp) once daily in patients with type 2 diabetes (T2D) inadequately controlled on oral anti‐diabetic drugs (OADs). Materi…
View article: Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer
Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer Open
Objectives In randomized-controlled crossover design trials, overall survival (OS) treatment effect estimates are often confounded by the control group benefiting from treatment received post-progression. We estimated the adjusted OS treat…
View article: Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma
Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma Open
Backgound Lenalidomide‐based regimens are commonly used for early relapse in patients with relapsed and/or refractory multiple myeloma (RRMM) receiving at least one prior line of therapy. In the absence of head‐to‐head comparison, matching…
View article: Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma
Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma Open
Lenalidomide-based regimens are commonly used for early relapse in patients with relapsed and/or refractory multiple myeloma (RRMM) receiving at least one prior line of therapy. In the absence of head-to-head comparison, matching-adjusted …
View article: CRNN-based splash audio event detection for fish monitoring
CRNN-based splash audio event detection for fish monitoring Open
Monitoring migratory fish species provides a good indicator for rivers' health.Migratory fish as alosa (Alosa fallax also known as twait shad), swims up the rivers to reproduce if the dam infrastructure allows it.During spawning, some spec…
View article: Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50%
Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50% Open
Background: For patients with advanced non-small-cell lung cancer (NSCLC) and high (⩾50%) programmed cell death-ligand 1 (PD-L1) expression, effective first-line immune-oncology monotherapies with significant survival benefits are approved…
View article: Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma
Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma Open
BACKGROUND: Most cutaneous squamous cell carcinomas (CSCCs) can be treated with surgical excision or radiation; however, approximately 1% of patients develop advanced disease. In 2018, the FDA approved cemiplimab-rwlc as the first programm…
View article: Gastrointestinal adverse events with insulin glargine/lixisenatide fixed‐ratio combination versus glucagon‐like peptide‐1 receptor agonist <scp>s</scp> in people with type 2 diabetes mellitus: A network meta‐analysis
Gastrointestinal adverse events with insulin glargine/lixisenatide fixed‐ratio combination versus glucagon‐like peptide‐1 receptor agonist <span>s</span> in people with type 2 diabetes mellitus: A network meta‐analysis Open
Aims Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are the recommended first injectable therapy in type 2 diabetes. However, long‐term persistence is suboptimal and partly attributable to gastrointestinal tolerability, particularly…
View article: Insulin glargine/lixisenatide fixed‐ratio combination ( <scp>iGlarLixi</scp> ) compared with premix or addition of meal‐time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta‐analysis
Insulin glargine/lixisenatide fixed‐ratio combination ( <span>iGlarLixi</span> ) compared with premix or addition of meal‐time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta‐analysis Open
Aim To assess the efficacy and safety of iGlarLixi, a fixed‐ratio combination of insulin glargine 100 U/mL and lixisenatide, relative to premix insulin and other insulin options through network meta‐analysis. Methods A systematic literatur…
View article: Efficacy and safety of <scp>iGlarLixi</scp> versus <scp>IDegLira</scp> in adults with type 2 diabetes inadequately controlled by glucagon‐like peptide‐1 receptor agonists: a systematic literature review and indirect treatment comparison
Efficacy and safety of <span>iGlarLixi</span> versus <span>IDegLira</span> in adults with type 2 diabetes inadequately controlled by glucagon‐like peptide‐1 receptor agonists: a systematic literature review and indirect treatment comparison Open
Aims To estimate the relative treatment effect between the fixed‐ratio combinations iGlarLixi and IDegLira (glucagon‐like peptide 1 receptor agonist with basal insulin) in people with type 2 diabetes inadequately controlled on a glucagon‐l…
View article: Author response for "Insulin glargine/lixisenatide fixed‐ratio combination ( <scp>iGlarLixi</scp> ) compared to premix or addition of meal‐time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta‐analysis"
Author response for "Insulin glargine/lixisenatide fixed‐ratio combination ( <span>iGlarLixi</span> ) compared to premix or addition of meal‐time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta‐analysis" Open
Aim To assess the efficacy and safety of iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL and lixisenatide, relative to premix insulin and other insulin options through network meta-analysis. Methods A systematic literatur…
View article: Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma
Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma Open
In this ITC, dupilumab was associated with lower severe asthma exacerbation rates and greater improvements in lung function than anti-IL-5s and omalizumab.
View article: BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis
BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis Open
Background: The analysis of the BRAF mutational status has been established as a standard procedure during diagnosis of advanced malignant melanoma due to the fact that BRAF inhibitors constitute a cornerstone in the treatment of metastati…
View article: BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis
BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis Open
Background: The analysis of the BRAF mutational status has been established as a standard procedure during diagnosis of advanced malignant melanoma due to the fact that BRAF inhibitors constitute a cornerstone in the treatment of metastati…